Turning Science Into Products™

SynDevRx, Inc. (“SDX”) Cambridge, Massachusetts, established in 2007, is developing new and effective treatments for metabolic-related diseases including pre-diabetes, diabetes, obesity, dyslipidemia and fatty liver disease as well as treatments for cancer.

Our treatments are best-in-class MetAP2 inhibitors of the fumagillin drug class.  SynDevRx lead compound, SDX-7320*, is a polymer conjugate of fumagillol which releases a pharmacologically active, novel fumagillol derivative in vivo. In animal models, SDX-7320 has shown improved activity relative to small molecule compounds in the fumagillin class.

Our drug development approach improves both the efficacy and safety of low molecular weight fumagillol-based drugs while reducing systemic drug exposure compared to the small molecule drug.  The expected clinical consequence of lowering systemic exposure is an improved safety profile.

The SDX development program targets metabolic-related diseases as well as cancer.  Our compounds inhibit MetAP2 - an enzyme which independent research has shown to be important in the regulation of a number of cellular processes including protein turnover, protein targeting and cell proliferation.  The polymer conjugation chemistry keeps the active drug inert in general circulation thereby greatly reducing systemic toxicities.  The conjugates also exhibit longer half-lives than fumagillol small molecules, which allows for less frequent dosing schedules than small molecules.

*This compound is currently in development and is not approved by the FDA (or any other regulatory authority) for clinical use.